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Abstract: The prevention and treatment of crystal deposition in the human body are based on
the understanding of the physicochemical properties underlying the precipitation of the sub-
stances involved. Among these properties, the solubilities of the crystals are very important.
Recently, experimentally determined solubility data of substances related to urolithiasis, such
as  calcium  oxalate  hydrates,  uric  acid  and  urates,  cystine,  and  xanthine,  were  critically
assessed. Unfortunately, reported solubilities of these substances were found to be either
scarce or in large disagreement. Consequently, detailed studies were carried out in our labo-
ratory, and the results will be discussed in this communication with emphasis on the ther-
modynamic consistency of the experimentally determined data. Since proper modeling of the
solubilities of these substances in artificial urine solutions serves as a prerequisite for solu-
bility predictions in real urine, the Joint Expert Speciation System (JESS) software package
was employed to create a comprehensive computer model including the relevant, low-molec-
ular inorganic and organic components of urine. The results of the simulations lead to some
useful suggestions regarding the prevention and treatment of stone disease. 
INTRODUCTION
Human body fluids are normally supersaturated with regard to several substances (e.g., blood plasma,
interstitial and intracellular liquors with respect to calcium carbonates and phosphates, particularly
hydroxyapatite and fluoroapatite; urine with respect to calcium oxalates and, depending on the pH, with
respect to uric acid or calcium phosphates). While normal biomineralization, like the formation of bone
and teeth, takes place in controlled biological situations, uncontrolled pathological crystallization leads
to painful or even life-threatening conditions such as calculi formation (renal, biliar, sublingual), devel-
opment of gout or arteriosclerosis, tissue calcification associated with cancer, etc. The question, why
pathological crystallization does not occur indiscriminately in all human fluids, has been discussed in
terms of three main factors: besides (i) the supersaturation as a necessary condition, the (ii) presence of
heterogeneous nucleants, and a (iii) deficit of crystallization inhibitors play a crucial role in pathologi-
cal situations [1].
In the scope of urolithiasis, more than 20 different types of stones composed of calcium oxalate
hydrates (hereafter, COM for monohydrate and COD for dihydrate), ammonium magnesium phosphate
(struvite), calcium phosphates (hydroxyapatite, HAP, and brushite, DCPD), uric acid and urates, cys-
tine and xanthine have been classified [2]. A sound knowledge of the solubilities of these substances is
necessary to understand the cause, prevention, and treatment of renal or bladder calculi. However in a
recent review, experimentally determined solubility data of these substances were critically assessed
and found to be either sparse or in large disagreement [3]. Consequently, a research program was con-
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July 2000. Other presentations are published in this issue, pp. 761–844.ducted in our laboratory to provide reliable solubility data of these compounds. This communication
summarizes the solubilities of calcium oxalate hydrates, uric acid and urates, cystine, and xanthine for
a wide range of experimental conditions, particularly those most pertinent to urolithiasis [4–11]. Special
care was taken to demonstrate the consistency of the equilibrium constants obtained in our laboratory
with other thermodynamic quantities. Our constants were then incorporated in databases of simulation
programs that permit solubility calculations in complex biological fluids. These simulations allow the




All experiments were performed in thermostatted, all-glass, percolation-type solubility cells. The pH
variation method (i.e., the variation of the initial H+ concentration) was used. Constant ionic strength
media were employed throughout to keep the activity coefficients of the reacting species essentially
constant. Thus, hydrogen ion concentrations (rather than activities) were measured potentiometrically
and hereafter p[H] = –log {[H+]/mol dm–3} will be used instead of pH. The metal ion and organic anion
concentrations were determined by AAS and UV spectrophotometry respectively. Further experimental
details can be found in refs. 3–11.
Calorimetry 
Dissolution enthalpies of uric acids and xanthine were measured using isoperibolic solution calorime-
ters. TRIS buffer solutions of appropriate pH were employed to increase solubility and to ensure a
defined final state of predominantly hydrogenurate and hydrogenxanthinate respectively. Details are
given in refs. 10 and 11.
MODELING
Computer simulations
Solubilities of calcium oxalate hydrates, calcium and magnesium phosphates were modeled using the
Joint Expert Speciation System (JESS) package of computer programs [12−14]. In these simulations,
all possible complexes were considered whose formation constants were taken from the JESS thermo-
dynamic database. In the present work, the urine model originally developed by Grases et al. [15] was
extended significantly. Compared to the model used in our previous review [3], the present one has a
considerable increase in the number of species (280), reactions (380), and thermodynamic quantities
(some 7200, mainly equilibrium constants but also standard potentials, Gibbs energies, enthalpies, and
heat capacities).
In the case of uric acid and urates, cystine, and xanthine, sophisticated simulation programs are
not necessary since there is only a small number of equilibrium constants required to model the solu-
bility in a great variety of salt solutions, including artificial urine.
Thermodynamic data
In our laboratory, solubility products (Ks0) were determined for the three calcium oxalate hydrates [4]
and for sodium and ammonium hydrogenurates [5,8]. So-called intrinsic solubility constants (Ks) were
measured for uric acid anhydrate and dihydrate [5], cystine [9], and xanthine [11]. In addition, first dis-
sociation constants (K1) of uric acid and xanthine were derived from solubility data [5,11]. All of these
constants were measured at various temperatures.
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um oxalate hydrates ([4], this work), uric acid anhydrate and dihydrate [10], and xanthine [11] were also
determined calorimetrically. In the case of cystine, solubilities were compared to values calculated
using protonation constants reported in literature.
XANTHINE, URIC ACID, AND URATES
Xanthine (C5H4N4O2) and uric acid (C5H4N4O3) are intermediate and final products, respectively, of
the purine metabolism in humans. Defects in the enzymatic activity of xanthine oxidase may lead to an
accumulation of either substance in urine [17]. 
The solubilities of these substances exhibit considerable dependencies on p[H] and temperature
[5–8,10,11], see Figs. 1–4. In the p[H] range of urine, three equilibrium constants are required to cal-
culate the solubility. In (1–3), uric acid anhydrate, the metastable uric acid dihydrate, and ammonium
hydrogenurate were taken as examples:
H2U(⋅2H2O)(s) → H2U(aq) (+ 2 H2O) Ks  (1)
H2U(aq) → H+(aq) + HU−(aq) K1 (2)
NH4HU(s) → NH4
+(aq) + HU−(aq) Ks0 (3)
Reactions (1,2) analogous to anhydrous uric acid hold true for xanthine. Solubility products of
sparingly soluble hydrogenxanthinates, analogous to (3), have not been reported. In both cases (uric
acid and xanthine), dissociation of the second proton occurs at p[H] values far exceeding the physio-
logically important range. Thus, the equilibrium constants (1−3) can be calculated from least-squares
analyses of solubility data.
The thermodynamic quantities describing the solubility of xanthine, as obtained in our laborato-
ry [11], are presented in Table 1 and Figs. 1 and 2. The enthalpy of solution calculated from the exper-
imentally determined solubility and first dissociation constants is ∆rH = 67.9 kJ mol−1. This value is in
excellent agreement with the calorimetric value ∆rH = (71.0 ± 1.3) kJ mol−1 [11]. Figure 2 reflects very
well the thermodynamic consistency of our experimentally determined data obtained from two differ-
ent methods, solubility and calorimetry. For comparison, literature data [18] are also shown in Figs. 1
and 2. Lister and Caldbick [18] reported the solubility data of xanthine in some buffer solutions from
which we obtained the solubility constants of pKs = 3.61 ± 0.03 and 3.28 ± 0.02 at 21 and 37 °C respec-
tively, and the first dissociation constants of pK1 = 7.39 ± 0.03 and 7.51 ± 0.02 at 21 and 37 °C respec-
tively [3,11]. The enthalpy of solution calculated from these data is ∆rH = 22.9 kJ mol−1, which differs
significantly from our calorimetric value [11]. The experimental technique applied, which led to a con-
siderably higher solubility, and the unreasonable decrease of the deprotonation constants with temper-
ature indicate that the authors of ref. 18 actually investigated supersaturated solutions. 
For the modeling of uric acid and hydrogenurate solubilities, a thermodynamically consistent set
of equilibrium constants and calorimetric data has also been obtained in our laboratory (see Tables 2
and 3 and Figs. 3 and 4) [5,10]. Moreover, our experimental results have proven that in the ionic
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Table 1 Solubility and first dissociation constants of xanthine, as derived
from solubility measurements at Ic = 0.300 mol dm−3 NaCl [11]. The
enthalpies of solution corresponding to the reaction H2Xan(s) → H+(aq) +
HXan−(aq) were measured calorimetrically [11].
t / °CpKs pK1 ∆rH / kJ mol−1
25 3.88 ± 0.02 7.43 ± 0.02 71.0 ± 1.3
37 3.69 ± 0.03 7.16 ± 0.03E. KÖNIGSBERGER AND L.-C. KÖNIGSBERGER
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Fig. 1 Solubility of xanthine at 25 and 37 °C (solid squares and circles respectively, [11]), and at 21 and 37 °C
(open triangles and circles respectively, [18]).
Fig. 2 Consistency of thermodynamic data for xanthine. Solid squares: equilibrium constants obtained from
solubility measurements; solid line corresponds to the calorimetrically determined enthalpy of solution [11].
Open symbols: literature data [18]; dotted line is the calculated slope of these data.
Fig. 3 Solubility of uric acids and urates at 37 °C. Uric acid anhydrate: open down triangles, in Standard
Reference Artificial Urine [6]; open up triangles, in 0.300 mol dm−3 NaCl + 0.050 mol dm−3 creatinine [6]; open
diamonds, in 0.300 mol dm−3 NaCl + 0.300 mol dm−3 urea [6]; solid circles, in 0.300 mol dm−3 LiCl [7].
Crosses [22] obviously correspond to uric acid dihydrate. Sodium hydrogenurate monohydrate: open circles, in
0.150 mol dm−3 NaCl [5]; ammonium hydrogenurate: open squares, in 0.300 mol dm−3 NH4Cl [8]. Curves were
calculated using the equilibrium constants given in Tables 2 and 3.strength range 0.15 ≤ Ic/mol dm−3 ≤ 0.30, the solubility of uric acid neither depends on the nature and
concentration of various inorganic components of urine nor on the presence of organic substances like
urea and creatinine [6]. Thus, the same solubility as in the other salt solutions was also found [6] in so-
called Standard Reference Artificial Urine, whose composition is given in ref. 21.
At 37 °C, the solubility of the metastable uric acid dihydrate exceeds that of the anhydrate by a
factor of about two. The solubility data obtained by Sperling and de Vries [22], which were also given
in ref. 23, obviously correspond to the dihydrate (Fig. 3). In fact, the uric acid samples of ref. 22 were
precipitated by acidification of real urine but were not characterized. It has been reported that under
these conditions of high supersaturation, uric acid dihydrate is formed [2].
Increasing the urinary pH by appropriate medication has been successfully used in the treatment
of uric acid lithiasis. Excessive alkalization, however, may cause precipitation of sodium or ammonium
hydrogenurates [24]. The latter substance has also been found together with struvite in infectious stones
caused by urea-splitting bacteria. Recently, it has been reported that in vitro, uric acid stones dissolve
better in lithium carbonate than in sodium or potassium (hydrogen)carbonate solutions; this behavior
was attributed to a litholytic effect of lithium ions [25]. Our measurements show, however, that uric acid
has the same solubility in lithium and sodium chloride solutions (Fig. 3). The increased solubility of
uric acid in lithium carbonate solutions is obviously due to a higher pH and to the fact that lithium
hydrogenurate has a higher solubility than the corresponding sodium and potassium salts (Table 3). The
latter compounds may form sparingly soluble precipitates on the surface of the uric acid calculus and
prevent further dissolution even if the pH is increased (see Fig. 3).
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Table 2 Solubility and first dissociation constants of uric acid, valid for various salt
solutions and artificial urine in the ionic strength range from 0.15 to 0.30 mol dm−3, as
derived from solubility measurements on uric acid anhydrate (H2U) and dihydrate
(H2U⋅2H2O) [5,6]. The enthalpies of solution corresponding to the reactions
H2U(⋅2H2O)(s) → H+(aq) + HU−(aq) (+ 2 H2O) were measured calorimetrically [10].
t / °CpKs pKs pK1 ∆rH / kJ mol−1
(H2U⋅2H2O) (H2U)
25 3.55 ± 0.01 3.76 ± 0.03 5.26 ± 0.04 Anhydrate:  56.3 ± 0.4
32 3.35 ± 0.01 3.63 ± 0.01 5.21 ± 0.01
37 3.21 ± 0.01 3.49 ± 0.03 5.19 ± 0.04 Dihydrate:  64.5 ± 0.2
42 3.08 ± 0.01 3.41 ± 0.01 5.13 ± 0.01
Fig. 4 Consistency of thermodynamic data for uric acid anhydrate (squares) and dihydrate (circles). Symbols are
derived from solubility measurements; the slopes of the lines were obtained calorimetrically.CYSTINE
L-cystine, C6H12N2O4S2, the least soluble of the naturally occurring amino acids, is normally excreted
in urine in low concentrations of ca. 0.06−0.17 mmol dm−3. Owing to a congenital defect in the tubu-
lar reabsorption of cystine, a small number of individuals excrete much higher concentrations of ca.
1.3−3.3 mmol dm−3 which results in the formation of calculi that can block the renal tubes [26].
The cystinate ion, Cis2−, can be protonated in four steps according to
n H+ + Cis2− → HnCisn−2 β01n = [HnCisn−2] [H+]−n [Cis2−]−1. (4)
In (4), n = 1.....4. and β01n denote the corresponding protonation constants. The formally uncharged
species H2Cis± (which is actually a zwitterion) has the lowest solubility, i.e.,
H2Cis(s) → H2Cis±(aq) (5)
and the corresponding (intrinsic) solubility constant is denoted as Ks. Thus, the solubility of cystine can
be calculated as analytical function of p[H] using five equilibrium constants (Table 4 and Fig. 5; see ref.
9). Although the protonation constants of cystine were measured at Ic = 0.15 mol dm−3, they reproduced
solubility data measured at Ic = 0.30 mol dm−3 very well.
The solubility of cystine in oxalate-free artificial urine was the same as in 0.30 mol dm−3 NaCl
[9]. However, owing to the precipitation of phosphates from artificial urine at higher p[H], data were
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(NaHU⋅H2O) (NH4HU) [Ca(HU)2⋅6H2O] (KHU) (LiHU⋅1.5H2O)
15 10.12 ± 0.07
25 4.61 ± 0.01 5.18 ± 0.03 9.81 ± 0.09
32 4.43 ± 0.01
37 4.31 ± 0.01 4.80 ± 0.01 9.28 ± 0.04 3.85 ± 0.05 2.75 ± 0.05
42 4.20 ± 0.01
45 9.01 ± 0.03 
aIc = 0.150 mol dm−3 NaCl; bIc = 0.300 mol dm−3 NH4Cl; cI = 0; dIc = 0.15 mol dm−3 LiCl.
Fig. 5 Solubility of L-cystine. At 25 °C: solid squares, 0.30 mol dm−3 NaCl [9]; open squares, 0.5 mol dm−3
NaCl [27]; dashed line, calculated using equilibrium constants of Table 4. At 37 °C: solid circles, oxalate-free
artificial urine; up-triangles, phosphate- and oxalate-free artificial urine; down-triangles, 0.30 mol dm−3 NaCl
[9]; open circles, real urine [28]; solid line, calculated using equilibrium constants of Table 4; dotted line,
calculated with JESS for phosphate- and oxalate-free artificial urine [9].only collected at p[H] < 5.0, while in phosphate-free artificial urine, cystine solubilities were measured
up to p[H] = 8.2. In the latter, a slightly higher solubility constant (0.88 mmol dm−3) was found, which
is most likely due to complex formation of cystine with Ca2+ and Mg2+, as was also confirmed by com-
puter simulations with JESS [9]. In normal artificial urine, on the other hand, alkaline earth ions are
complexed to phosphate. However, a significant dependence of the intrinsic solubility on the nature and
concentration of various inorganic salts was reported in ref. 31; so more experimental work on this topic
is certainly needed. Recent literature data for 0.5 mol dm−3 NaCl [27] agree with our values at low p[H]
but show a systematic deviation at high p[H] (Fig. 5).
Cystine solubilities in real urine [28] agree well with our results obtained in synthetic solutions
[9]. Therefore, the equilibrium constants in Table 4 permit reasonable cystine solubility estimates for
urine. It should be emphasized again that the excellent agreement between our measured solubility data
and values calculated with independently determined protonation constants supports the reliability of
both data sets.
For the treatment of cystine lithiasis, potassium citrate has been used to increase the urinary pH
and thus the cystine solubility [32]. However, at higher pH, the risk of calcium phosphate calculi for-
mation becomes higher. This problem would be particularly serious if a recent recommendation [33] to
use THAM (tris-(hydroxymethylene)-aminomethane) buffer at pH = 10 for in vivo cystine chemolysis
were applied. Even at pH ≈ 7, significant HAP precipitation is not only predicted by computer simula-
tions [15] but also observed experimentally [15,34].
CALCIUM OXALATES
In contrast to the substances discussed above, the solubility of COM, the major component of oxalate
calculi, is almost p[H] independent in the urinary p[H] range, as was shown by computer simulations
and confirmed experimentally [4]. However, the calcium oxalate solubility strongly depends on the con-
centration of ions that form complexes with calcium or oxalate, such as citrate or magnesium ions [3].
It was demonstrated that our urine model [3,4] permits reliable solubility calculations by taking all of
these complexes into account.
Owing to its importance for renal lithiasis, the solubility products of COM, COD, and COT (cal-
cium oxalate trihydrate) have been determined frequently. Nevertheless, the reliability of the early lit-
erature data is rather unsatisfactory; these include the values reported in refs. 35 and 36, which, based
on the number of citations, have obviously been regarded as reliable. To clarify this point, a simple ther-
modynamic consistency test is applied according to a knowledge existing for some 120 years [37]. This
rule states that the enthalpies of dissolution become progressively more endothermic with extent of
hydration, since the enthalpies of dehydration, corresponding to e.g. COT → COD + H2O(aq) or 
COD → COM + H2O(aq) are always positive [38]. The enthalpies of solution derived from our solu-
bility products [4] given in Table 5 obey this rule (Table 6) while those of refs. 35 and 36 do not.
Moreover, our data also agree very well with values determined calorimetrically (see Fig. 6). It should
also be noted here that our thermodynamic quantities for uric acid anhydrate and dihydrate pass this
consistency test as well (see Table 2 and Fig. 4).
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Table 4 Solubility and protonation constants for L-cystine used for solubility simulations in 0.30 mol dm−3 NaCl
and oxalate-free artificial urine at 25 and 37 °C.
t / °C − log Ks 
a log β011 log β012 log β013 log β014
25 3.22 ± 0.01 8.80 b 16.83 b 18.41 c 20.03 c
37 3.08 ± 0.01 8.604 ± 0.003 c 16.356 ± 0.004 c 18.41 ± 0.01 c 20.03 ± 0.02 c
aIc = 0.30 mol dm−3 NaCl [9]; 
bt = 20 °C, Ic = 0.15 mol dm−3 NaClO4 [29]; 
ct = 37 °C, Ic = 0.15 mol dm−3 NaCl [30].The enthalpy of dissolution of COM was determined calorimetrically as shown in Table 7; a sim-
ilar determination was carried out for COT with the required modification of reactions (A) and (D). Due
to the low solubility in water, the enthalpy of dissolution of COM and COT was determined in 0.10 mol
dm−3 HCl. Thus, a thermodynamic cycle was employed at constant ionic strength (Ic = 0.10 mol dm−3)
to obtain the enthalpy of the desired reaction (Table 7). If ∆rHI is the enthalpy of reaction valid for ionic
strength I, ∆rHI = ∆rH°+   ν L2
I + xL 1
I, where ν and x are the moles of ions (ν = 2) and water 
(x = 1, 2, or 3) resulting from the dissolution of one mole of the solid substance, and L2
I and L1
I are the
relative partial molar enthalpies of solute and solvent at ionic strength I, respectively. For the ionic
strength used in the present calorimetric study, L1
I can certainly be neglected and 2 L2
I for a 2:2 elec-
trolyte is estimated to 2.1 ± 0.5 kJ mol−1. 
Urolithiasis is controlled by thermodynamic and kinetic factors either alone or in combination.
The reason is that the crystallization potential of urine is related not only to the concentration of any
particular  compound  but  also  to  the  presence  or  absence  of  others,  such  as  complexing  agents,
inhibitors, or promoters of the crystallization of the compound in question. Crystallization inhibitors
frequently cause the actual concentration products to exceed the corresponding solubility products. In
this way, urine is supersaturated (metastable) with respect to some substances, and kinetic factors play
an important role to prevent or delay the precipitation of the substances. As supersaturation increases,
a threshold is reached at which urine can hold no more salt in solution and kinetic factors are no longer
effective. A correlation between the COM supersaturation in real urine samples and the results of a sim-
ple clinical test for urinary lithogen risk (ULR) was recently reported in an application of computer
modeling in urolithiasis research [42]. This correlation leads to an establishment of kinetic and ther-
modynamic factors contributing to stone formation.
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Table 5 Solubility products of the three calcium oxalate hydrates valid for 




20 8.84 ± 0.02 8.42 ± 0.02 8.33 ± 0.01
25 8.77 ± 0.01 8.34 ± 0.02 8.24 ± 0.01
30 8.71 ± 0.01 8.26 ± 0.03 8.12 ± 0.02
37 8.65 ± 0.03 8.17 ± 0.03 8.02 ± 0.02
40 8.62 ± 0.02 8.13 ± 0.04 7.97 ± 0.02
Table 6 Dissolution enthalpies of calcium oxalate hydrates, corresponding to the reaction
CaC2O4. n H2O(s) → Ca2+ + C2O4
2− + n H2O (I = 0). The values obtained from
precipitation reactions were multiplied by (–1). 
∆rH°/ kJ mol−1
calorimetric
ln Ks0 vs. 1/T
this work [4] literature [35,36]
COM 20.8 ± 0.8a 18.9 ± 0.9 17.3 ± 1.3
19.8 ± 1.2b
16.7 ± 0.6c
COD 24.3 ± 1.4d 25.6 ± 0.5 14.1 ± 1.3
COT 30.5 ± 2.3e 32.1 ± 1.2 25.1 ± 0.7
adissolution, 25 °C [39]; bprecipitation, 25 °C [40]; cprecipitation, 37 °C [40]; dprecipitation, 25 °C
[41]; edissolution, 25 °C (this work, 4 measurements).The ULR test results indicate the positive or negative risk of urinary calcium stone formation and
the absorbance A = 0.3 has been established as the border line between normal and lithogenic urines
[43]. Results of this test and the supersaturation values of COM obtained from the urines of stone-for-
mers and healthy people are shown Fig. 7. It can be seen clearly that almost all human urines are super-
saturated with respect to COM and as expected, urines of most healthy people give negative ULR test
results. Six samples from this group give positive results, and their log S values were employed to estab-
lish a region called “kinetic threshold” which was found to be 0.40 < log S < 0.57 for the crystalliza-
tion of COM. Five cases corresponding to kinetic and/or thermodynamic control of urinary stone for-
mation were defined, and they are presented as regions I, II, III, IV, and V in Fig. 7.
I. In region I, 0 < log S < 0.57 and A < 0.3 mean that the kinetic factors effectively keep calcium
ions in solution. The presence of most of the data obtained from healthy people implies the
absence of heterogeneous nucleants and/or the presence of some natural crystallization inhibitors
in urine. The existence of about 1/3 of the data obtained from the stone-formers indicates that
although having normal urine, these patients suffer some abnormal renal morphoanatomy, e.g.,
papillary necrosis or strongly disordered urodynamic conditions [43].
II. In region II, 0 < log S < 0.40 and A > 0.3, COM crystallized from all urine samples. Data from
stone-formers are found exclusively which indicates the absence of crystallization inhibitors in
their urines as well as abnormal morphoanatomy of their kidneys.
III. Region III or the kinetic threshold consists of data with 0.40 < log S < 0.57 and A > 0.3. The width
of this region depends on the uncertainties involved in the analyses of the samples. Six lithogen-
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Table 7 Dissolution enthalpy of COM at 298.15 K.
Reaction ∆rH / kJ mol−1
(A) CaC2O4
.H
2O(s) + 2 H+ → Ca2+ + H2C2O4 + H2O (Ic = 0.10 mol dm−3 HCl) 30.3 ± 0.6a
(B) 2 Na+ + H2C2O4 → Na2C2O4(s) + 2 H+ (Ic = 0.10 mol dm−3 HCl) −25.5 ± 0.3b
(C) Na2C2O4(s) → 2 Na+ + C2O4
2− (Ic = 0.10 mol dm−3 (CH3)4NCl) 18.1 ± 0.1c
−2 L2 (Ic = 0.10 mol dm−3) −2.1 ± 0.5
(D) CaC2O4
.H2O(s) → Ca2+ + C2O4
2− + H2O (I = 0) 20.8 ± 0.8
a13 measurements; b9 measurements; c4 measurements.
Fig. 6 Thermodynamic consistency of calcium oxalate data. Solid symbols [4], open symbols [35,36]. Squares:
COM; circles: COD; triangles: COT. Solid lines correspond to calorimetrically determined enthalpies of solution,
dashed lines were obtained by linear regression (Table 6).ic samples from the healthy group found in this region signal that these people have excellent
renal morphology so no stones were formed in their urinary tracts though the salt crystallized in
the ULR test [43].
IV. In region IV, log S > 0.57 and A > 0.3, thermodynamic factors are in absolute control and kinet-
ic factors do not have any effects even if there were inhibitors present in the tested urines.
Obviously, the supersaturation values are abnormally high so the only result here is the crystal-
lization of calcium oxalate. This is confirmed by the fact that only data from active stone-form-
ers with positive ULR test results are found in this region.
V. Region V (log S > 0.57 and A < 0.3) does not contain any data since inhibitors are no longer effec-
tive at such high supersaturation.
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Fig. 7 Correlation between ULR test and COM supersaturation [42]. Open symbols: stone-formers and solid
symbols: healthy people.
Fig. 8 Effect of 1:10 dilution on supersaturation of COM in standard reference artificial urine, as simulated with
JESS. Solid line: all components are diluted with pure water; dashed line: the original MgSO4 concentration is
kept constant and all other components are diluted; dotted line: three times the original MgSO4 concentration is
kept constant and all other components are diluted.This work shows that a failure in kinetic inhibition and/or the presence of heterogeneous nucle-
ants are the main reasons for COM crystal development in urine. Nevertheless, abnormally high super-
saturation values can lead to calculi formation since there are about 10% of data obtained from the
stone-former group and none from the healthy group found in region IV. Consequently, for urines
belonging to this region IV, it would be necessary to decrease the supersaturation prior to the adminis-
tration of crystallization inhibitors, such as phytic acid, that are used as a pharmacological treatment of
stone disease [1].
A frequent recommendation to calcium oxalate stone-formers is to consume a large quantity of
liquid. However, our computer simulations demonstrate that this advice is only physicochemically
meaningful for some certain fluids. The effect of dilution with pure water on the p[H] and COM super-
saturation of standard reference artificial urine is shown in Fig. 8. Since only an unrealistically high
1:10 dilution results in an unsaturated solution, pure water does not seem to effect a significant reduc-
tion of the supersaturation. More likely, it only contributes to a faster flow of urine through kidney cav-
ities and thus a removal of sediments. However, mineral waters containing complexing agents like mag-
nesium can certainly reduce the supersaturation to a higher extent (Fig. 8). It was also concluded from
the results of a recent study on 85 human subjects [44] that such mineral waters reduce the risk of cal-
cium oxalate stone formation.
CONCLUSIONS
This paper summarizes solubility data for various substances found in kidney stones that have been
reported by our group. The data have been measured for wide ranges of temperature, p[H], and con-
centrations of inorganic salts and organic substances, including conditions most pertinent to urolithia-
sis. The thermodynamic quantities derived from these solubility data have been proven to be very reli-
able by 
• the thermodynamic consistency of the results obtained from different experimental techniques
and/or
• the excellent agreement between experimental and calculated solubilities.
These  thermodynamic  quantities  were  then  used  in  computer  simulations  that  lead  to  some
judgement and suggestions regarding to the cause, prevention, and treatment of stone diseases.
• Treatment of uric acid, cystine and, to a lesser extent, xanthine lithiasis by increasing urinary pH
is effective. However, excessive alkalization may lead to the formation of calcium phosphate cal-
culi and also sodium or ammonium hydrogenurate precipitation in the case of elevated uric acid
concentrations.
• The formation of COM calculi is mainly caused by a failure in kinetic inhibition and/or the pres-
ence of heterogeneous nucleants, thus treatment using crystallization inhibitors such as phytic
acid has been suggested [1]. Nevertheless, in a minor group of stone-formers, it is necessary to
lower abnormally high COM supersaturation before crystallization inhibitor therapy is applied.
Our computer simulations also show that a large consumption of pure water is not a suitable treat-
ment of COM calculi because it does not significantly reduce the supersaturation of COM in
urine. A high intake of fluids containing complexing agents such as magnesium would be better
for the reduction of supersaturation.
Recently, so-called nanobacteria were found in kidney stones and have been claimed to induce
calcifications in urine that eventually lead to urolithiasis [45]. Although this topic is still under discus-
sion, it has been suggested that a simple tetracycline therapy may help people who suffer from chronic
stone formation.
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